Kevin Dat Vuong, M.A.

- **Instructor of Neurology**

Graduate School

M.A., State University of New York, Binghamton, N.Y.

Undergraduate School

B.A., University of California, Irvine, Calif.

Research Interests

Statistical analysis, database management and psychometrics in assessing the various components of movement disorders

Contact Information

Kevin Dat Vuong, M.A.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-5427
Fax: 713-798-3853
Email: datn@bcm.edu

Journal Publications

1. Ondo WG, Meilak C, Vuong KD. Predictors of battery life for the Activa Soletra 7426 Neurostimulator. Parkinsonism Relat Disord. 2007;13(4):240-2. [View journal article]
2. Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006;21(5):692-5. [View journal article]
3. Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr. 2006;11(7):501-8. [View journal article]
4. Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12(6):382-7. [View journal article]
5. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592-7. [View journal article]
6. Ondo WG, Wang A, Thomas M, Vuong KD. Evaluating factors that can influence spirography ratings in patients with essential tremor. Parkinsonism Relat Disord. 2005;11(1):45-8. [View journal article]
7. Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005;20(1):44-7. [View journal article]
8. Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004;63(6):1096-8. [View journal article]
9. Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics. 2004;114(5):1203-5. [View journal article]
10. Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61(9):1393-7. [View journal article]
11. Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27(6):274-7. [View journal article]

12. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia. 2004;24(1):60-5. [View journal article]
13. Thomas M, Jankovic J, Suteerawattananon M, Wankadia S, Caroline KS, Vuong KD, et al. Clinical Gait and Balance Scale (GABS): validation and utilization. J Neurol Sci. 2004;217(1):89-99. [View journal article]
14. Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003;18(10):1190-2. [View journal article]
15. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-8. [View journal article]
16. Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003;18(12):1530-3. [View journal article]
17. Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003;60(11):1595-8. [View journal article]
18. Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology. 2003;61(8):1093-7. [View journal article]
19. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031-5. [View journal article]
20. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-4. [View journal article]
21. Ondo W, Dat Vuong K, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001;16(6):1137-42. [View journal article]
22. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57(8):1392-6. [View journal article]
23. Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678-82. [View journal article]
24. Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord. 2000;6(4):237-240. [View journal article]
25. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology. 2000;55(9):1404-6. [View journal article]

Poster and Platform Presentations

1. Sitburana O, Rountree S, Vuong KD, Ondo W . Weight change in parkinson and alzheimer patients taking atypical antipsychotic drugs. Mov Disord. 2007;22 Suppl 16:S190. [View poster]
2. Diamond AL, Vuong KD, Jankovic J. Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life. Mov Disord. 2006;21 Suppl 15:S669. [View poster]
3. Diamond AL, Vuong KD, Jankovic J. Deep brain stimulation of the subthalamic nucleus on Parkinson's disease: Effects on quality of life. Ann Neurol. 2006;60 Suppl 10:S77. [Previously Presented] [View poster]
4. Kenney CJ, Vuong K, Hunter C, Almaguer M, Jankovic J. Long term safety of deep brain stimulation for the treatment of Parkinson's disease. Neurology. 2006;66(5 Suppl 2):A49-50.
5. Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Neurology. 2005;64(6 Suppl 1):A255. [Previously Presented] [View poster]
6. Azher SN, Vuong KD, Shahed J, Diamond AL, Jankovic J . Gait and balance assessment in parkinsonian disorders. Mov Disord. 2005;20 Suppl 10:S112-3. [View poster]
7. Diamond AL, Shahed J, Azher SN, Vuong KD, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2005;20 Suppl 10:S153-4. [View poster]
8. Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine: Does prior history of depression preclude this drug as a treatment option? Mov Disord. 2005;20 Suppl 10:S47. [View poster]
9. Mejia N, Vuong KD, Hunter C, Jankovic J. Medications associated with the onset of tardive dyskinesia. Mov Disord. 2005;20 Suppl 10:S18. [View poster]
10. Ondo WG, Meilak C, Vuong KD, Jankovic J. Predictors of battery life for the Activa® Soletra 7426 neurostimulator. Mov Disord. 2005;20 Suppl 10:S160-1. [View poster]
11. Shahed J, Diamond AL, Vuong KD, Jankovic J. Characteristics of Parkinson's disease in patients with childhood-onset essential tremor. Mov Disord. 2005;20 Suppl 10:S169-70. [View poster]

12. Jankovic J, Hunter CB, Vuong KD . Safety and efficacy of tetrabenazine in the treatment of Huntington's disease and other choreas. Mov Disord. 2004;19(9):1127. [View poster]
13. Silay Y, Jankovic J, Vuong KD, Almageur M, Ondo WG, Tintner R, et al. The safety of deep brain stimulation in patients with Parkinson's disease, essential tremor, and other movement disorders. Ann Neurol. 2004;56 Suppl 8:S54-5. [View poster]
14. Hunter C, Vuong KD, Mejia N, Jankovic J . Tetrabenazine, a monoamine depleter, effective in the treatment of Tourette syndrome. Mov Disord. 2004;19 Suppl 9:S437. [View poster]
15. Jankovic J, Hunter C, Mejia N, Vuong KD. Tetrabenazine: Effective treatment for tardive dyskinesia. Mov Disord. 2004;19 Suppl 9:S73. [View poster]
16. Silver GA, Vuong KD, Jankovic J. Young-onset versus late-onset Parkinson's disease: Clinical features and disease progression. Mov Disord. 2004;19 Suppl 9:S264. [View poster]
17. Thomas M, Banuelos P, Vuong KD, Jankovic J. Long-term prognosis of psychogenic movement disorders. Mov Disord. 2004;19 Suppl 9:S431. [View poster]
18. Thomas M, Vuong KD, Jankovic J. Psychogenic dystonia: Clinical characteristics and long-term progression. Mov Disord. 2004;19 Suppl 9:S111. [View poster]
19. Vuong KD, Hunter C, Mejia N, Jankovic J. Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders. Mov Disord. 2004;19 Suppl 9:S422. [View poster]
20. Hunter CB, Vuong KD, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Neurology. 2004;62(7 Suppl S5):A506-7. [View poster]
21. Jankovic J, Madisetty J, Vuong KD. Essential tremor in children. Neurology. 2004;62(7 Suppl S5):A502. [View poster]
22. Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: Long-term outcome. Neurology. 2004;62(7 Suppl S5):A501. [View poster]
23. Silay YS, Vuong KD, Jankovic J . The efficacy and safety of fluphenazine in patients with Tourette syndrome. Neurology. 2004;62(7 Suppl S5):A506. [View poster]
24. Jankovic J, Hunter CB, Vuong KD . Tetrabenazine in the treatment of chorea. Presented at the American Society for Experimental NeuroTherapeutics (ASENT), 6th Annual Meeting in Bethesda, Md. (March 11-13, 2004) [View poster]
25. Ondo WG, Romanyshyn J, Vuong KD . Long term treatment of restless legs syndrome with dopamine agonists. Neurology. 2003;60(5 Suppl 1):A291. [View poster]
26. Hill AN, Jankovic J, Vuong KD, Donovan D . Treatment of hypophonia with collagen vocal fold augmentation in patients with parkinsonism. Mov Disord. 2002;17 Suppl 5:S105. [View poster]
27. Hunter CB, Wang A, Vuong KD, Jankovic J . Age-related tolerability of tetrabenazine. Mov Disord. 2002;17 Suppl 5:S41. [View poster]
28. Hunter CB, Wang A, Vuong KD, Jankovic J . Tetrabenazine in the treatment of Tourette syndrome. Mov Disord. 2002;17 Suppl 5:S341. [View poster]
29. Ondo WG, Wang A, Thomas M, Vuong KD . Evaluating factors that can influence spirography ratings in patients with essential tremor. Mov Disord. 2002;17 Suppl 5:S344. [View poster]
30. Tintner R, Almaguer M, Vuong KD, Ondo WG, Jankovic J, Sanghera M. Predictors of response to bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord. 2002;17 Suppl 5:S208.
31. Jankovic J, Ahsan J, Vuong KD. Comparison of immunogenicity of old versus current Botox in cervical dystonia. Presented at the Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, International Conference in Hannover, Germany (June 8, 2002). [View poster]
32. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A (Botox) for chronic daily headache: A randomized placebo-controlled, parallel design study. Headache. 2002;42(5):414. [View poster]
33. Atassi F, Vuong KD, Jankovic J, Ondo WG. The prevalence of restless legs syndrome in patients with Parkinson's disease. Neurology. 2001;56(8 Suppl 3):A21.
34. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson's disease and restless legs syndrome. Neurology. 2001;56(8 Suppl 3).
35. Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine treatment for dopaminergic induced hallucinations. Presented at the Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).
36. Ondo WG, Vuong KD, Atassi F, Khan H, Kwak C, Jankovic J. Daytime sleepiness in patients with Parkinson's disease. Presented at the Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).

37. Vuong KD, Ondo WG, Almaguer M, Simpson RK, Jankovic J. Unilateral thalamic deep brain stimulation for essential tremor and Parkinson's disease: Effects of stimulation on the non-target limb and rebound augmentation. Neurology. 2000;54(Suppl 3):A54.